FDA Approvals 2012 - FDA Approval Stocks - New FDA Approvals

Home
Investing in Stocks
Stock Picks
Today's Biggest Stock Gainers
Today's Biggest Stock Losers
2014 Stock Gainers
2014 Penny Stock Gainers
Stocks 2015
Top Stocks 2015
Top Penny Stocks 2015
Stocks to Buy 2015
Oil Stocks to Buy 2015
Best Solar Stocks 2015
Top Gold Stocks 2015
Top Silver Stocks 2015
Dividend Stocks 2015
Bank Stocks 2015
Tech Stocks 2015
IPO's in 2014
Cramer Stock Picks 2015
Icahn Stock Picks 2015
Top 10 Stocks 2015
Top 10 Penny Stocks
Best Coffee Stocks 2015
Best China Stocks 2015
Best Marijuana Stocks 2015
Best Ebola Stocks 2015
Hot OTC Stocks
Long Term Stocks
Dividend Stocks
Penny Stocks to Buy
How to Day Trade
Stock Trading Rules
Best Performing Stocks
Pink Sheets Stocks
OTC Stocks
Site Map
Contact Us

advanced web statistics

FDA Approval Stocks 2012 - Latest FDA Approval Stock News

What stocks received FDA Approval in 2012?  A company receives FDA Approval when the FDA committee votes in favor of a medical device or a drug.  This FDA news usually has a positive effect on the stock after the company receives the new approval.  From cancer drugs to weight loss drugs, the FDA votes for against every drug in clinical trials.  Orphan drug status allows a company to received FDA approval quicker and is usually a good sign of how effective the drug actually is.  Below is a list of the latest new FDA Approvals in 2012.

Latest 2012 Stock Picks - Click Here

New FDA Approvals 2012 - Medivation, Inc. (MDVN) - Medivation, Inc. (MDVN) received FDA Approval for their prostate cancer drug in September 2012 - U.S. FDA Approves XTANDI(R) (enzalutamide) After Priority Review for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel - MDVN stock soars to a new 52 week high at $105 on the FDA news.  MDVN has been one of the best performing cancer stocks in 2012. - MDVN FDA News

FDA Approval for Weight Loss Drugs in 2012 - Vivus (VVUS) & Arena Pharmaceuticals (ARNA)

Vivus (VVUS) Announces FDA Approval of Once Daily Qsymia™ (Phentermine and Topiramate Extended-release) Capsules CIV

THE FIRST ONCE DAILY COMBINATION TREATMENT FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WHO ARE OBESE OR OVERWEIGHT WITH A WEIGHT-RELATED COMORBIDITY - Link

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BELVIQ (pronounced BEL-VEEK) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes). The indication includes the following limitations of use: The safety and efficacy of coadministration of BELVIQ with other products intended for weight loss and the effect of BELVIQ on cardiovascular morbidity and mortality have not been established.  Link

My Stock Forum
Stocks to Buy
Visit My Stock Message Board Today



My Stock Forum
stockstobuy.org
Join Stockstobuy.org Today!